Growth equity

Private equity funds raised in recent years hold far more undeployed capital than earlier vintages at the same stage in their life, PEI Group data shows.

The firm started raising the strategy in Q2 and aims to reach final close by Q1 next year as more funds emerge in this space, Private Equity International has learned.

A more pressing need for control and operational value creation is blurring the lines between the two strategies.

The combination of the two firms, which will create the world's largest healthcare private equity investor, will change how healthcare investing is done by linking East and West opportunities, its co-chief executives tell PEI.

After a surge in interest around the covid-19 pandemic, it has been a mixed picture for life sciences and biotech-focused PE fundraising and capital deployment.

The Tokyo Stock Exchange is increasing minimum market capitalisation for companies listed in its Growth Market section to ¥10bn by 2030.

The agribusiness sector is yet to recover from fading interest in the wake of the covid-19 pandemic.

Germany, Austria and Switzerland, dependable as a group, are not immune to global fundraising woes.

There are countless private markets firms that need a partner to help them grow in an era of scarce alpha and capital, says Arctos managing partner Ian Charles.

Southeast Asia, once touted as the continent’s next big thing in private equity, is struggling to live up to expectations. What’s holding the region back?